Trade

Concord Drugs share price

High risk
  • 50%Low risk
  • 50%Moderate risk
  • 50%Balanced risk
  • 50%High risk
  • 50%Extreme risk
  • ₹79.89(-1.02%)
    February 6, 2026 15:14:00 PM IST
    • NSE
    • BSE
  • Vol : 3.66 K (NSE + BSE)
    Last 20 day avg : 10.10 K

Concord Drugs is trading -1.02% lower at Rs 79.89 as compared to its last closing price. Concord Drugs has been trading in the price range of 80.80 & 77.90. Concord Drugs has given -2.15% in this year & 14.74% in the last 5 days. Concord Drugs has TTM P/E ratio 115.42 as compared to the sector P/E of 23.40.The company posted a net profit of 0.19 Crores in its last quarter.Listed peers of Concord Drugs include Sun Pharmaceutical Industries (-0.43%), Divi's Laboratories (-1.78%), Torrent Pharmaceuticals (-1.04%).The Mutual Fund holding in Concord Drugs was at -% in . The MF holding has - from the last quarter. The FII holding in Concord Drugs was at -% in . The FII holding has - from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Feb 07, 2026, 08:19 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.89
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.56
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    2.37
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    139.67
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -3.24
    Indicates undervaluation
Price range
Day Range
Lowest
77.90
Highest
80.80
52 week range
Lowest
26.10
Highest
92.52
Concord Drugs Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
Neutral
1,694.90-0.434,06,653.7035.565.660.970.50
Divi's Laboratories
Bearish
6,027.00-1.781,60,509.2873.2610.740.500.01
Torrent Pharmaceuticals
Neutral
3,931.65-1.041,33,059.5570.6417.940.8017.62
Cipla
Moderately Bearish
1,330.80-0.141,07,490.2120.353.430.980.81
Dr Reddy's Laboratories
Neutral
1,241.60-0.291,03,622.8618.253.080.652.34
Concord Drugs Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-02-14Quarterly Results
2025-11-13Quarterly Results
2025-08-08Quarterly Results
2025-05-23Audited Results
2025-03-17Preferential Issue of shares & Others
About the company Concord Drugs
  • IndustryBiotechnology & Drugs
  • ISININE858L01010
  • BSE Code538965
  • NSE Code
Concord Drugs Limited is an India-based pharmaceutical company. The Company's principal activity is to manufacture licensed drugs based on the formulations approved. The Company is focused on developing drug delivery systems, including multiple unit pellet system (MUPS), sustained release, and modified release pellets. It operates a Current Good Manufacturing Practice (cGMP) contract manufacturing formulation-fill-finish facility, offering a full spectrum of pharmaceutical development and manufacturing services for drug products. The Company's products include pharmaceutical ready to fill pellets, MUPS; tissue bio adhesive; injectables (small volume parenterals); oral solid dosages (tablets); oral solid dosages (capsules); liquid orals, and dry syrup (powder). It also offers hand sanitizers under the brand name, PROTON SAFE. It manufactures hand sanitizers on third party basis also. The Company's oral liquid dosage forms include solutions, syrups, and suspensions.
  • Management Info
  • Seelam ReddyExecutive Chairman of the Board, Managing Director
  • Seelam ReddyChief Financial Officer, Whole time Director
  • Namratha NaglaCompliance Officer, Company Secretary
  • S. Manoj ReddyAdditional Whole-Time Director
Concord Drugs Share Price FAQs

Concord Drugs is trading at 79.89 as on Fri Feb 06 2026 09:44:00. This is -1.02% lower as compared to its previous closing price of 80.71.

The market capitalization of Concord Drugs is 79.80 Cr as on Fri Feb 06 2026 09:44:00.

The 52 wk high for Concord Drugs is 92.52 whereas the 52 wk low is 26.10

Concord Drugs can be analyzed on the following key metrics -

  • TTM P/E: 115.42
  • Sector P/E: 23.40
  • Dividend Yield: 0.00%
  • D/E ratio: 0.56

Concord Drugs reported a net profit of 0.34 Cr in 2025.

Quick Links
EQUITY QUICK LINKS
Concord Drugs QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Concord Drugs share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.